Indivior Pharmaceuticals, Inc.
INDV
$36.76
-$1.07-2.83%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 19.17% | 19.73% | 2.28% | 1.00% | -6.34% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 19.17% | 19.73% | 2.28% | 1.00% | -6.34% |
| Cost of Revenue | -9.09% | 14.29% | -17.86% | -34.18% | 15.79% |
| Gross Profit | 24.77% | 20.80% | 6.77% | 13.64% | -9.76% |
| SG&A Expenses | -8.27% | -11.43% | 0.00% | 3.95% | -6.99% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | 66.67% | -125.00% | -- | -- |
| Total Operating Expenses | -14.07% | -8.54% | -7.91% | -10.12% | -4.78% |
| Operating Income | 117.91% | 150.94% | 26.09% | 69.05% | -10.67% |
| Income Before Tax | 98.28% | 113.16% | 23.33% | 151.67% | -19.44% |
| Income Tax Expenses | 136.36% | -223.53% | -162.50% | 291.30% | 0.00% |
| Earnings from Continuing Operations | 89.36% | 385.71% | 90.91% | 118.56% | -22.95% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 89.36% | 385.71% | 90.91% | 118.56% | -22.95% |
| EBIT | 117.91% | 150.94% | 26.09% | 69.05% | -10.67% |
| EBITDA | 111.43% | 145.45% | 23.96% | 61.36% | -12.50% |
| EPS Basic | 89.37% | 394.27% | 101.56% | 120.04% | -15.50% |
| Normalized Basic EPS | 144.85% | 200.90% | 33.84% | 67.39% | -11.67% |
| EPS Diluted | 82.06% | 376.07% | 106.25% | 119.44% | -15.50% |
| Normalized Diluted EPS | 137.24% | 193.17% | 30.69% | 66.04% | -11.72% |
| Average Basic Shares Outstanding | 0.00% | -1.75% | -5.30% | -7.41% | -8.82% |
| Average Diluted Shares Outstanding | 3.20% | 0.81% | -3.01% | -6.67% | -8.76% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |